Global Health

submitted by George Hurlburt

Sierra Leonean doctors practice wearing protective clothing in the Ebola Training Academy in Freetown, Sierra Leone, December 16, 2014. Reuters

uk.reuters.com - by Kemo Cham and Emma Farge - October 21, 2015

. . . the case of Scottish nurse Pauline Cafferkey – the first known Ebola survivor to have an apparently life-threatening relapse – has revived concerns about the health of some 17,000 survivors in Sierra Leone, neighbouring Guinea and Liberia.

Doctors and health officials in Sierra Leone told Reuters that a handful of mystery deaths among discharged patients may also be types of Ebola relapses, stirring fear that the deadly virus may last far longer than previously thought in the body, causing other potentially lethal complications.

Diagnoses have not been made, partly because of a lack of relevant medical training and insufficient equipment for detecting a virus that can hide in inaccessible corners of the body - such as the spinal fluid or eyeball. In Cafferkey's case, the virus in her brain caused meningitis.

(READ COMPLETE ARTICLE)

submitted by Carrie La Jeunesse

nejm.org - October 14, 2015 - DOI: 10.1056/NEJMe1512928

The number of new cases of Ebola virus disease (EVD) in western Africa has declined from a peak of 1063 cases in the week of October 9, 2014, to fewer than 10 confirmed cases per week for 11 consecutive weeks as of October 7, 2015. The main mode of transmission is direct contact with the blood or body fluids of a person with EVD or from the body of a person who died from EVD. However, Ebola virus can persist in the body fluids of survivors during convalescence, which may result in transmission of the virus. The potential for the persistence of Ebola virus in the semen of male survivors raises concern regarding the possible transmission of the virus to sexual partners.

(CLICK HERE - READ COMPLETE ARTICLE)

INTELLECTUAL PROPERTY WATCH by Catherine Saez, Oct, 12, 2015

(Scroll down for Ministers' Statement.)

The health ministers of the Group of Seven (G7) most developed countries have issued a declaration on antimicrobial resistance and Ebola. The governments said they would explore innovative economic incentives to promote research and development of new antibiotics, such as a global antibiotic research fund and a market entry reward mechanism.

The G7 (Canada, France, Germany, Italy, Japan, United Kingdom, and United States) met from 8-9 October in Berlin and agreed to the Berlin Declaration [pdf] on Antimicrobial Resistance – Global Union for Antibiotics Research and Development (GUARD), aimed at supporting developing countries to develop national antimicrobial resistance action plans.

The G7 health ministers also issued a commitment on lessons learned from Ebola, and supported the 2005 World Health Organization International Health Regulations (IHR), insisting on the need to comply with them.